The Japan Neurology Clinical Trials market is projected to grow from $325.1 Mn in 2022 to $518.1 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022 - 2030. The market will be driven by the high prevalence of neurological diseases and a robust healthcare system. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis, Pfizer, Eisai Co., Ltd & Daiichi Sankyo.
The Japan Neurology Clinical Trials market is projected to grow from $325.1 Mn in 2022 to $518.1 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022 - 2030. According to research published in the Journal of Alzheimer's Diseases in March 2021 in Japan, there would be between 6.5 million and 7 million individuals with dementia in 2025 and 8.5 million to 11.5 million people with dementia in 2060. Similarly, Alzheimer's disease is responsible for 50-75% of dementia cases in Japan. In Japan, the yearly prevalence of Parkinson's disease (PD) is stated to be 50-80 per 100,000, and it is fast growing since ageing is a key risk factor for PD. As a result, the high prevalence of the neurological disease is likely to raise demand for clinical trials to come up with more drugs targeted to the therapy for those conditions.
Clinical trials in neurology are varied and address a wide range of neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke. These studies are being done to improve patient treatment choices, create novel medicines, and advance our knowledge of the underlying processes of neurological illnesses. Japan has a well-established clinical trial sector and was regarded as a leader in neurology research. A high frequency of neurological illnesses, a competent healthcare system, and a supportive regulatory environment all contribute to Japan's success in this domain. The Japanese government created the Clinical Research Network Japan (CRN), a nationwide network of hospitals and medical institutes that cooperate together on clinical research. The CRN offers clinical trial assistance and resources, such as centralised ethical review and data management services.
Novartis, Pfizer, Biogen, Sanofi, and Eisai were among the worldwide pharmaceutical and biotechnology corporations undertaking neurology clinical studies in Japan. In addition, numerous Japanese pharmaceutical firms, including Takeda, Otsuka, and Astellas, were undertaking neurology clinical studies. In September 2022, Eisai, a Japanese pharmaceutical company, said that its experimental medicine lecanemab had helped halt cognitive deterioration in adults in the early stages of Alzheimer's disease.
Market Growth Drivers
One significant reason is the country's unusually high frequency of neurological illnesses in comparison to other advanced economies. As a result, there is an increasing desire for innovative treatments and therapies, which is driving investment in clinical research in the area of neurology.
Another driver is Japan's superior healthcare infrastructure and a favourable regulatory framework that fosters clinical research investment. Japan has a well-established clinical trial market, and the government has taken a number of initiatives such as the establishment of Clinical Research Network Japan (CRN), a nationwide network of hospitals and medical institutes to make clinical trials more convenient in the nation as well as faster approval procedures for specific kinds of studies.
One of the most significant restraints is the ageing population, which may make recruiting subjects for clinical studies more challenging. Moreover, there may be cultural and language challenges that hinder participant recruitment and retention, especially for international organisations conducting trials in Japan. Some firms face the high expense of performing clinical trials in Japan. Additionally, there may be legislative and administrative barriers that make conducting clinical trials in the nation more challenging.
In September 2022, Eisai, a Japanese pharmaceutical company, reported promising trials for a new Alzheimer's drug. Announced that its experimental medicine lecanemab had helped halt cognitive deterioration in adults in the early stages of Alzheimer's disease.
1. Report Description of the Japan Neurology Clinical Trials Market
1.1 Research Scope and Assumption
1.2 Objective of the study
1.3 Research Methodology
1.4 Reason to buy the report
2. Japan Neurology Clinical Trials Market Executive Summary
2.1 Japan Neurology Clinical Trials Market –Industry Snapshot & key buying criteria, 2021-2030
2.2 Market Size, Growth Prospects, and Key findings
3. Market Dynamics of Japan Neurology Clinical Trials Market
3.1 Market Growth Drivers Analysis
3.2 Market Restrains Analysis
4. Japan Neurology Clinical Trials Market Segmentation
4.1 By Phase
4.1.1 Phase I
4.1.2 Phase II
4.1.3 Phase III
4.1.4 Phase IV
4.2 By Study Design Outlook
4.2.2 Parkinson's Disease (PD)
4.2.3 Huntington's Disease
4.2.5 Traumatic Brain Injury (TBI)
4.2.6 Amyotrophic Lateral Sclerosis (ALS)
4.2.7 Muscle regeneration
4.3 By Indication Outlook
4.3.3 Expanded Access
5. Japan Neurology Clinical Trials Market Share
5.1 Market Analysis, Insights, and Forecast – By Revenue
6. Competitive Landscape
6.1 Major Top Market Players
7. Key Company Profiles
7.1 Company 1
7.1.2 Financial Performance
7.1.3 Product & Services
7.1.4 Strategic initiatives
7.2 Company 2
7.2.2 Financial Performance
7.2.3 Product & Services
7.2.4 Strategic initiatives
7.3 Company 3
7.3.2 Financial Performance
7.3.3 Product & Services
7.3.4 Strategic initiatives
7.4 Company 4
7.4.2 Financial Performance
7.4.3 Product & Services
7.4.4 Strategic initiatives
7.5 Company 5
7.5.2 Financial Performance
7.5.3 Product & Services
7.5.4 Strategic initiatives
8. Healthcare Policies and Regulatory Landscape
8.1 Healthcare Policies in Japan
8.2 Regulatory Framework in Japan
8.3 Pricing & Reimbursement Scenario in Japan Neurology Clinical Trials Market
9. Factors Driving Future Growth
9.1 New Trends and Development Japan Neurology Clinical Trials Market
9.2 Future Opportunities
10. Strategic Recommendations
By Phase (Revenue, USD Billion):
By Study Design Outlook (Revenue, USD Billion):
By Indication Outlook (Revenue, USD Billion):
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses